Search Results - "Marchetti, Paolo"

Precision medicine in breast cancer: From clinical trials to clinical practice by Crimini, Edoardo, Repetto, Matteo, Aftimos, Philippe, Botticelli, Andrea, Marchetti, Paolo, Curigliano, Giuseppe

“…Breast cancer (BC) is the most common cancer in women and, despite the undeniable improvements in the outcome of these patients obtained in the last decade,…”
Get full text

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs by Capalbo, Carlo, Scafetta, Giorgia, Filetti, Marco, Marchetti, Paolo, Bartolazzi, Armando

“…Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However,…”
Get full text

Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer by Vernocchi, Pamela, Gili, Tommaso, Conte, Federica, Del Chierico, Federica, Conta, Giorgia, Miccheli, Alfredo, Botticelli, Andrea, Paci, Paola, Caldarelli, Guido, Nuti, Marianna, Marchetti, Paolo, Putignani, Lorenza

“…Several studies in recent times have linked gut microbiome (GM) diversity to the pathogenesis of cancer and its role in disease progression through immune…”
Get full text

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? by Botticelli, Andrea, Cerbelli, Bruna, Lionetto, Luana, Zizzari, Ilaria, Salati, Massimiliano, Pisano, Annalinda, Federica, Mazzuca, Simmaco, Maurizio, Nuti, Marianna, Marchetti, Paolo

“…Immune checkpoint inhibitors have revolutionized the treatment paradigm of highly lethal malignancies like advanced non-small cell lung cancer (NSCLC),…”
Get full text

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment by Botticelli, Andrea, Vernocchi, Pamela, Marini, Federico, Quagliariello, Andrea, Cerbelli, Bruna, Reddel, Sofia, Del Chierico, Federica, Di Pietro, Francesca, Giusti, Raffaele, Tomassini, Alberta, Giampaoli, Ottavia, Miccheli, Alfredo, Zizzari, Ilaria Grazia, Nuti, Marianna, Putignani, Lorenza, Marchetti, Paolo

“…Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20-30% of treated patients present long term benefits. The metabolic changes occurring in…”
Get full text

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions by Greco, A., de Vincentiis, Marco, Marchetti, Paolo, Fiore, Marco, Angeletti, Diletta, Visconti, Irene Claudia, Botticelli, Andrea, Ralli, Massimo, Lambiase, Alessandro

“…Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic…”
Get full text

Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy by Capone, Imerio, Marchetti, Paolo, Ascierto, Paolo Antonio, Malorni, Walter, Gabriele, Lucia

“…Nowadays, several types of tumors can benefit from the new frontier of immunotherapy, due to the recent increasing knowledge of the role of the immune system…”
Get full text

Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study by Muscaritoli, Maurizio, Lucia, Simone, Farcomeni, Alessio, Lorusso, Vito, Saracino, Valeria, Barone, Carlo, Plastino, Francesca, Gori, Stefania, Magarotto, Roberto, Carteni, Giacomo, Chiurazzi, Bruno, Pavese, Ida, Marchetti, Luca, Zagonel, Vittorina, Bergo, Eleonora, Tonini, Giuseppe, Imperatori, Marco, Iacono, Carmelo, Maiorana, Luigi, Pinto, Carmine, Rubino, Daniela, Cavanna, Luigi, Di Cicilia, Roberto, Gamucci, Teresa, Quadrini, Silvia, Palazzo, Salvatore, Minardi, Stefano, Merlano, Marco, Colucci, Giuseppe, Marchetti, Paolo

“…In cancer patients, malnutrition is associated with treatment toxicity, complications, reduced physical functioning, and decreased survival. The Prevalence of…”
Get full text

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events by Cortellini, Alessio, Bersanelli, Melissa, Santini, Daniele, Buti, Sebastiano, Tiseo, Marcello, Cannita, Katia, Perrone, Fabiana, Giusti, Raffaele, De Tursi, Michele, Zoratto, Federica, Marconcini, Riccardo, Russano, Marco, Zeppola, Tea, Anesi, Cecilia, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Tudini, Marianna, Silva, Rosa Rita, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Migliorino, Maria Rita, Mallardo, Domenico, Vanella, Vito, Mosillo, Claudia, Bracarda, Sergio, Rinaldi, Silvia, Berardi, Rossana, Natoli, Clara, Ficorella, Corrado, Porzio, Giampiero, Ascierto, Paolo A.

“…Several studies have found an association between higher body mass index (BMI) and improved clinical outcomes in cancer patients receiving programmed cell…”
Get full text

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable by Cortellini, Alessio, Bersanelli, Melissa, Buti, Sebastiano, Cannita, Katia, Santini, Daniele, Perrone, Fabiana, Giusti, Raffaele, Tiseo, Marcello, Michiara, Maria, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Marconcini, Riccardo, Malorgio, Francesco, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Antonini Cappellini, Gian Carlo, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Pergolesi, Federica, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Iacono, Daniela, Gelibter, Alain, Occhipinti, Mario Alberto, Parisi, Alessandro, Porzio, Giampiero, Fargnoli, Maria Concetta, Ascierto, Paolo Antonio, Ficorella, Corrado, Natoli, Clara

“…Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. We conducted a…”
Get full text

Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis by Botticelli, Andrea, Cirillo, Alessio, Strigari, Lidia, Valentini, Filippo, Cerbelli, Bruna, Scagnoli, Simone, Cerbelli, Edoardo, Zizzari, Ilaria Grazia, Rocca, Carlo Della, D'Amati, Giulia, Polimeni, Antonella, Nuti, Marianna, Merlano, Marco Carlo, Mezi, Silvia, Marchetti, Paolo

“…The monoclonal antibodies anti-programmed death protein-1 (anti-PD-1) nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved…”
Get full text

CT based radiomic approach on first line pembrolizumab in lung cancer by Zerunian, Marta, Caruso, Damiano, Zucchelli, Alberto, Polici, Michela, Capalbo, Carlo, Filetti, Marco, Mazzuca, Federica, Marchetti, Paolo, Laghi, Andrea

“…Clinical evaluation poorly predicts outcomes in lung cancer treated with immunotherapy. The aim of the study is to assess whether CT-derived texture parameters…”
Get full text

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients by Cortellini, Alessio, Chiari, Rita, Ricciuti, Biagio, Metro, Giulio, Perrone, Fabiana, Tiseo, Marcello, Bersanelli, Melissa, Bordi, Paola, Santini, Daniele, Giusti, Raffaele, Grassadonia, Antonino, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Malorgio, Francesco, Garufi, Carlo, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Iacono, Daniela, Migliorino, Maria Rita, Porzio, Giampiero, Cannita, Katia, Ficorella, Corrado, Buti, Sebastiano

“…Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in…”
Get full text

The Fascinating Chemistry of α‐Haloamides by Fantinati, Anna, Zanirato, Vinicio, Marchetti, Paolo, Trapella, Claudio

“…The aim of this review is to highlight the rich chemistry of α‐haloamides originally mainly used to discover new C−N, C−O and C−S bond forming reactions, and…”
Get full text

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice by Cortellini, Alessio, Tucci, Marco, Adamo, Vincenzo, Stucci, Luigia Stefania, Russo, Alessandro, Tanda, Enrica Teresa, Spagnolo, Francesco, Rastelli, Francesca, Bisonni, Renato, Santini, Daniele, Russano, Marco, Anesi, Cecilia, Giusti, Raffaele, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, Occhipinti, Mario Alberto, Marconcini, Riccardo, Vitale, Maria Giuseppa, Nicolardi, Linda, Chiari, Rita, Bareggi, Claudia, Nigro, Olga, Tuzi, Alessandro, De Tursi, Michele, Petragnani, Nicola, Pala, Laura, Bracarda, Sergio, Macrini, Serena, Inno, Alessandro, Zoratto, Federica, Veltri, Enzo, Di Cocco, Barbara, Mallardo, Domenico, Vitale, Maria Grazia, Pinato, David James, Porzio, Giampiero, Ficorella, Corrado, Ascierto, Paolo Antonio

“…BackgroundConcomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint…”
Get full text

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives by Barchiesi, Giacomo, Mazzotta, Marco, Krasniqi, Eriseld, Pizzuti, Laura, Marinelli, Daniele, Capomolla, Elisabetta, Sergi, Domenico, Amodio, Antonella, Natoli, Clara, Gamucci, Teresa, Vizza, Enrico, Marchetti, Paolo, Botti, Claudio, Sanguineti, Giuseppe, Ciliberto, Gennaro, Barba, Maddalena, Vici, Patrizia

“…In locally advanced (LA) breast cancer (BC), neoadjuvant treatments have led to major achievements, which hold particular relevance in HER2-positive and…”
Get full text

Global mapping of cancers: The Cancer Genome Atlas and beyond by Ganini, Carlo, Amelio, Ivano, Bertolo, Riccardo, Bove, Pierluigi, Buonomo, Oreste Claudio, Candi, Eleonora, Cipriani, Chiara, Di Daniele, Nicola, Juhl, Hartmut, Mauriello, Alessandro, Marani, Carla, Marshall, John, Melino, Sonia, Marchetti, Paolo, Montanaro, Manuela, Natale, Maria Emanuela, Novelli, Flavia, Palmieri, Giampiero, Piacentini, Mauro, Rendina, Erino Angelo, Roselli, Mario, Sica, Giuseppe, Tesauro, Manfredi, Rovella, Valentina, Tisone, Giuseppe, Shi, Yufang, Wang, Ying, Melino, Gerry

“…Cancer genomes have been explored from the early 2000s through massive exome sequencing efforts, leading to the publication of The Cancer Genome Atlas in 2013…”
Get full text

Design of Nanosystems for the Delivery of Quorum Sensing Inhibitors: A Preliminary Study by Hallan, Supandeep Singh, Marchetti, Paolo, Bortolotti, Daria, Sguizzato, Maddalena, Esposito, Elisabetta, Mariani, Paolo, Trapella, Claudio, Rizzo, Roberta, Cortesi, Rita

“…Biofilm production is regulated by the Quorum Sensing system. Nowadays, Quorum Sensing represents an appealing target to design new compounds to increase…”
Get full text

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial by Sobrero, Alberto, Lonardi, Sara, Rosati, Gerardo, Di Bartolomeo, Maria, Ronzoni, Monica, Pella, Nicoletta, Scartozzi, Mario, Banzi, Maria, Zampino, Maria Giulia, Pasini, Felice, Marchetti, Paolo, Cantore, Maurizio, Zaniboni, Alberto, Rimassa, Lorenza, Ciuffreda, Libero, Ferrari, Daris, Zagonel, Vittorina, Maiello, Evaristo, Barni, Sandro, Rulli, Eliana, Labianca, Roberto

“…Purpose Given the cumulative neurotoxicity associated with oxaliplatin, a shorter duration of adjuvant therapy, if equally efficacious, would be advantageous…”
Get full text

Cytotoxicity of Isoxazole Curcumin Analogs on Chronic Myeloid Leukemia-Derived K562 Cell Lines Sensitive and Resistant to Imatinib by Feriotto, Giordana, Marchetti, Paolo, Rondanin, Riccardo, Tagliati, Federico, Aguzzi, Serena, Beninati, Simone, Casciano, Fabio, Tabolacci, Claudio, Mischiati, Carlo

“…Despite curcumin (CUR) inhibiting cell proliferation in vitro by activating apoptotic cell death, its use in pharmacological therapy is hampered by poor…”
Get full text